On this page
This learning module explores the nature of opioid dependence and the diagnostic criteria for opioid use disorder, then outlines the use of pharmacotherapies in medication assisted treatment of opioid dependence (MATOD) and the benefits of opioid agonist treatment including long-acting injectable buprenorphine (LAIB) products.
This is a an introductory module to opioid dependence treatment; if you would like to extend your learning with real world patients (and gain MO CPD hours) we recommend enrolling in one of our related opioid dependence treatment audits after completion of this activity.
Learning outcomes
On completion of this educational activity participants will be able to:
Explain the characteristic features of opioid dependence, and common illicit and licit opioid drugs that can cause dependence and addiction and their associated harms.
Outline the challenges faced by opioid dependent patients who attend a pharmacy or clinic for regular supervised dosing of opioid agonist therapy (OAT).
Outline the benefits of becoming an OAT prescriber, and identify ways in which long-acting injectable buprenorphine (LAIB) products may mitigate some of the concerns and challenges around daily dosing.
Determine the differences between different LAIB formulations.
Long-acting injectable buprenorphine for the treatment of opioid dependence - Education
Long-acting injectable buprenorphine for the treatment of opioid dependence - Evaluation
Sponsored by
Related content
Audits
EA:
1.5
MO:
15
RP:
1.5
Total:
18
Opioid Dependence Treatment (ODT) flexi-audit
Modules
EA:
1
MO:
0
RP:
0
Total:
1
On-demand webinar - The opioid dependence treatment landscape is changing: What every GP needs to know
Modules
EA:
1
MO:
1
RP:
0
Total:
2
Practical use of long-acting injectable buprenorphine for the treatment of opioid dependence